Clinical trial · Interventional
Effect of Addition of Dexmedetomidine or Ketamine to Intravenous Infusion of Lidocaine on Proinflammatory Cytokines in Pelvi-abdominal Cancer Surgeries.
Effect of Dexmedetomidine/Lidocaine, Ketamine/Lidocaine and Lidocaine Alone on Proinflammatory Cytokines in Pelvi-abdominal Cancer Surgeries: Randomised Prospective Study
NCT06631625CI-TRIAL-00081386completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators hypothesize that effect of addition of dexmedetomidine or ketamine by IV infusion to lidocaine infusion may be more beneficial than lidocaine infusion alone on proinflammatory cytokines (IL-1, IL-6 and TNFα), and postoperative pain relief and decreased opioid consumption, reduced Length of stay.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Abdominal Cancer | Malignant Abdominal Neoplasm | ALIAS | 0.90 |
| Pelvic Cancer | Malignant Pelvic Neoplasm | ALIAS | 0.90 |
| Proinflammatory Cytokines | — | UNRESOLVED | — |
| Surgery | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| lidocaine and dexmedetomidine infusion | Drug | — | UNRESOLVED |
| Lidocaine and ketamine | Drug | — | UNRESOLVED |
| Lidocaine Intravenous Infusion | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Group L receiving intravenous lidocaine infusion only
- description
- Patients will receive 1.5mg /kg lidocaine 2%; intravenously as a bolus dose then 1.5mg/kg/hr lidocaine infusion using a 50cc syringe pump intra-operatively.
- interventionNames
- Drug: Lidocaine Intravenous Infusion
- type
- EXPERIMENTAL
- label
- Group LK receiving lidocaine and ketamine infusion
- description
- Patients will receive same infusion regimen of lidocaine 2%; as in group L plus 0.35 mg/kg ketamine intravenously as a bolus dose, followed by intravenous infusion of 0.2 mg/kg/h using a 50cc syringe pump intra- operatively.
- interventionNames
- Drug: Lidocaine and ketamine
- type
- EXPERIMENTAL
- label
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 40 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Age 40-70 years. * Female patients. * ASA physical status class I or II. * Elective resectable pelvi-abdominal cancer. Exclusion Criteria: * Patients with history of sensitivity to the studied drugs. * Patients with cardiac conduction defects. * Impaired kidney or liver function. * Psychiatric disease or seizure disorder requiring medication within the previous 2 years. * Opioid tolerant patient. * Patient receiving nonsteroidal anti-inflammatory drugs within 1 week of surgery. * Patient receiving B blockers, α2 ad-renergic agonist, sedatives, and antiarrythemic drugs. * Cognitive dysfunction. * Any history of antitumor treatments before surgery.
References
Publications (1)
- RESULTHassan MM, Saleh RG, Abdalla NO, Radwan NH, Abdelghfar EM. Effect of lidocaine infusion compared to dexmedetomidine infusion on proinflammatory cytokines and stress response in pelvi-abdominal cancer surgeries: a randomized clinical trial. Anaesth. pain intensive care 2021;26 (1):44-52. DOI: 10.35975/apic.v26i1.1765